Ossium HPC

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
12 patients (estimated)
Sponsors
Ossium Health, Inc.
Collaborators
Center for International Blood and Marrow Transplant Research
Tags
Allogeneic Stem Cell Transplant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2126
NCT Identifier
NCT05589896

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.